Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
PRNewswire - November 17, 2003
"The rapid expansion confirms our expectation of the market demand for our HIV test in China," said Stephen Sham, Chairman and CEO of MedMira. "We are extremely pleased to find such rapid acceptance in the Chinese point-of- care diagnostic industry. Chinese authorities and agencies are making extraordinary efforts to curb the spread of HIV and we are very pleased to see that our technology is making such immediate in-roads and becoming a significant component of their public health campaign."
This distributor commitment in China comes shortly after MedMira's announcement they had shipped a total of 250,000 rapid HIV test kits to the USA, in the first 4 months following the United States Food and Drug Administration (FDA) approval of MedMira's HIV tests.
Long Hao Healthcare Technology Company Ltd. has its head office in Guangzhou, China. Long Hao introduced the overseas drug store business model into China, where they successfully operate a network of 10,000 retail stores.
In addition, Long Hao distributes a variety of healthcare products for oncology, cardiovascular and general health, within China.
MedMira (http://www.medmira.com) is a commercial biotechnology company that develops, manufactures and markets qualitative, in vitro diagnostic tests for the detection of antibodies to certain diseases, such as HIV, in human serum, plasma or whole blood.
All of MedMira's diagnostic tests are based on the same flow-through technology platform, thus facilitating the development of future products. MedMira's technology provides a quick (under 3 minutes), accurate, portable, safe and cost-effective alternative to conventional laboratory testing.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
SOURCE MedMira Inc.
031117
PR031126
Copyright © 2003 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019 http://www.prnewswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .